Anlon Healthcare reported a net profit of ₹354.69 lakh for the quarter ended June 30, 2025. The company recorded revenue from operations of ₹3,329.72 lakh for the first quarter of FY26. Total income for the period stood at ₹3,330.89 lakh, while total expenses were reported at ₹2,830.48 lakh.

The board of directors approved the unaudited standalone financial results at a meeting held on November 11, 2025. The results were reviewed by the Audit Committee prior to board approval. R V D & Co., Chartered Accountants, provided the Independent Auditor's Review Report, confirming that the financial statements were prepared in accordance with Indian Accounting Standard 34 (Ind AS 34).

Financial Performance

The company's profit before tax for the quarter was ₹500.41 lakh. Following a tax expense of ₹145.72 lakh, the profit after tax was finalized at ₹354.69 lakh. Basic and diluted earnings per equity share for the quarter were reported at ₹2.22.

Key Financial Metrics (Standalone)

Balance Sheet Highlights

As of June 30, 2025, the company's total assets stood at ₹19,775.76 lakh, an increase from ₹18,129.99 lakh as of March 31, 2025. Total current assets rose to ₹17,534.74 lakh from ₹15,848.09 lakh in the previous fiscal year end. Trade receivables increased to ₹9,365.71 lakh from ₹7,499.87 lakh.

On the liabilities side, total equity and liabilities reached ₹19,775.76 lakh. Current liabilities increased to ₹7,292.70 lakh as of June 30, 2025, compared to ₹6,005.22 lakh as of March 31, 2025. Borrowings, including current and non-current financial liabilities, were recorded at ₹5,842.07 lakh.

Anlon Healthcare Limited has informed the stock exchanges that its Chairman & Managing Director, Mr. Punitkumar Rasadia, has been invited for a television interview on NDTV Profit. The interview is scheduled to be telecast live on June 11, 2026, at 01:30 P.M. IST under the program "The Small Cap Buzzers". The disclosure was submitted to BSE Limited and The National Stock Exchange of India Ltd. on June 11, 2026, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Discussion Topics

The interaction will focus on the company's growth journey, recent business developments, and financial performance for FY 2025-26. The discussion will also cover the future outlook of the company. The company confirmed that the discussion would be based solely on publicly available information and no unpublished price-sensitive information (UPSI) would be shared during the interview.

Key Details of the Interaction

Anlon Healthcare noted that the interview could be cancelled, rescheduled, or postponed depending on circumstances. The company has requested the exchanges to take the information on record.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE0Y8W01025/4a8aaf29e41244a3.pdf